Plné znění - 80/2017 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2017 - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

80/2017 Sb. m. s.

Sdělení

INFORMACE

80

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx sdělení Ministerstva xxxxxxxxxxxx věcí x. 58/2007 Sb. x. x. x č. 46/2008 Sb. x. x.

 

Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx xxx 28. xxxxxxxxx 2016 xxxx generální xxxxxxxxxx XXXXXX oznámeno schválení xxxxxx znění Xxxxxxx X (Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xxx xxx 2017 - Xxxxxxxxxxx xxxxxxxx) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾.

X novým zněním Xxxxxxx X vyslovil xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx a xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx změn Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx znění Xxxxxxx X vstoupilo x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx dne 1. xxxxx 2017 x xxx Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 30. xxxxx 2017.

Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X x platnost xxxxxxxx platit xxxxx Xxxxxxx I platné xx 1. xxxxx 2016, xxxxxxxxx pod č. 26/2017 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx xxxxxxx xxxxxx se xxxxxxxxx xxxxxxxx.

XXXXXXX XXXXXXXXXXXXX KODEX

SEZNAM XXXXXXXXXX XXXXX A XXXXX XXXXXXX XXX XXX 2017

MEZINÁRODNÍ XXXXXXXX

Xxxxxxxxx xxxx Seznamu xxxx xxxxxxxxx WADA x xxxx publikován x xxxxxxxxxx a xxxxxxxxxxxxx.

X xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxx xxxx xxxxxxxxxxx anglická xxxxx.

Xxxxx Xxxxxx xxxx platný xx 1. ledna 2017 

XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2017

XXXXXXX XXXXXXXXXXXXX KODEX

Platný od 1. xxxxx 2017

Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx S1, X2, X4.4, X4.5 x S6(a) a Xxxxxxxxxx metod X1, X2 x M3.

LÁTKY X XXXXXX XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)

ZAKÁZANÉ LÁTKY

S0. XXXXXXXXXXX XXXXX

Xxxxxxxxx farmakologicky xxxxxx látka, xxxxx xxxx zahrnuta x xxxxxxxxxxxxx xxxxxxx Seznamu x xxxx aktuálně xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. léčiva x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx ukončené xxxxxxxxxx, xxxxxxxxxx drogy, xxxxx schválené xxxxx xxx veterinární použití), xx zakázána xxxxx.

X1. XXXXXXXXXX LÁTKY

Anabolické xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (AAS):

(a) Xxxxxxxx* XXX, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-norpregna-4-en-17α-ol);

fluoxymesteron;

formebolon;

furazabol (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-hydroxy-2α,17α-dimethyl-5α-androstan-3-on);

methyldienolon (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestr-4-en-3-on);

methyItestosteron;

metribolon (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(tetrahydropyran-2-yl)oxy]-1’H-pyrazolo[3,4:2,3]-5α-androstane);

quinbolon;

stanozolol;

stenbolon;

1-testosteron (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx** AAS, xxxxx xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol);

androstendion (androst-4-en-3,17-dion);

boldenon;

boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxxxx-3xx); 

xxxxxxxxx (19-xxxxxxxxxxxxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-hydroxyandrost-5-en-17-on);

testosteron;

a xxxxxx xxxxxxxxxx x isomery, xxx ne s xxxxxxxx xxxxx na xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (androst-5-en-3,17-dion);

androsteron;

epi-dihydrotestosteron;

epitestosteron;

etiocholanolon;

3ß-hydroxy-5α-androstan-17-on;

7α-hydroxy-DHEA;

7ß-hydroxy-DHEA;

7-keto-DHEA;

19-norandrosteron;

19-noretiocholanolon.

2. Xxxxxxx xxxxxxxxxx látky, xxxxxxxxxx:

Xxxxxxxxxxx; selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX, xxxx. andarin x xxxxxxx); xxxxxxx; xxxxxxx x zilpaterol, xxx xx x omezením xxxxx na xx.

Xxx xxxxx xxxxxxx této xxxxx: * "exogenní" xx xxxxxxxx k xxxxx, xxxxxx xxxx normálně xxxxxxxxx xxxxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxx.

X2. XXXXXXXXX XXXXXXX, XXXXXXX FAKTORY, XXXXXXXX XXXXX X XXXXXXXX

Xxxxxxxxxxx xxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx účinky xxxx zakázány:

1. Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx:

1.1 Xxxxx xxxxxxxxxxx erytropoesu (XXX) xxxxxx xxxx.

xxxxxxxxxxxx (dEPO);

erytropoetinů (XXX);

XXX-Xx;

XXX-xxxxxxxxxxx xxxxxxx (XXX), xxxx. XXXX 530 x peginesatid;

inhibitory XXXX, xxxx. X-11706;

xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX);

xxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (TGF-beta), xxxx. xxxxxxxxxxx, luspatercept;

1.2 Xxxxxxxx neerytropoetického XXX xxxxxxxxx, např.

ARA-290;

asialo XXX;

xxxxxxxxxxxxx XXX;

2. Xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), xxxx. xxxxxx, xxxxxxxxxx x xxxxxxxxxx (XX-4592); x xxxxxxxxxx XXX, xxxx. argon x xxxxx.

3. Xxxxxxxxxxxxxxxxxx (CG) x xxxxxxxxxxxx xxxxxx (XX) x xxxxxx xxxxxxxxxx faktory, např. xxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxxx, u xxxx.

4. Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx faktory, např. xxxxxxxxxxxx.

5. Xxxxxxx xxxxxx (XX) a xxxx xxxxxxxxxx faktory včetně: xxxxxxx uvolňujícího xxxxxxx xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. XXX-1295, sermorelinu a xxxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX), např. xxxxxxxx a mimetik xxxxxxxx, např. xxxxxxxxxxx x ipamorelinu; xxxxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx (XXXX), xxxx. xxxxxxxxxxxxx, XXXX-6, xxxxxxxxxx a xxxxxxxxxxxx (XXXX- 2).

Xxxxx xxxx xxxx xxxxxxxx xxxxxxxxxxx xxxxxxx faktory:

Fibroblastové xxxxxxx xxxxxxx (FGFs); xxxxxxxxxxxx xxxxxxx faktor (XXX); insulinu xxxxxxx xxxxxxx faktor-1 (XXX-1) x jeho xxxxxxx; xxxxxxxxxx růstové xxxxxxx (XXX); xxxxxxx xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (PDGF); vaskulárně-endoteliární xxxxxxx xxxxxx (VEGF), xxxxxx jako xxxxxxxxx xxxx růstové xxxxxxx xxxxxxxxxxx syntézu xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx ovlivňující xxxx xxxxxxxxx vláken.

S3. XXXX2- XXXXXXXX

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx beta2- agonisté, xxxxxx všech xxxxxxxxx xxxxxxx, xxxx xxxxxxxx.

Xxxxxxxx (xxx xx x xxxxxxxx pouze na xx):

Xxxxxxxxx; xxxxxxxxxx; higenamin; xxxxxxxxxxx; olodaterol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; salmeterol; xxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx jsou:

• inhalační xxxxxxxxxx: maximálně 1600 xxxxxxxxxx za 24 xxxxx, nepřekročit 800 xxxxxxxxxx xx každých 12 hodin;
• inhalační xxxxxxxxxx: xxxxxxxxx dodaná xxxxx 54 mikrogramů za 24 xxxxx;
• xxxxxxxxx salmeterol: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin.

Přítomnost xxxxxxxxxxx v xxxx x xxxxxxxxxxx xxxxx xxx 1000 ng/ml x přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx nebude xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx použití, xxx xxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxx nález, xxxxx sportovec neprokáže xxxxxxxxxxxxx farmakokinetickou studií, xx abnormální xxxxxxxx xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxx (x xxxxxxxx) xxxxx, xxx xxxx uvedená xxxxxxxxx xxxxx.

X4. XXXXXXXXX A XXXXXXXXXXX MODULÁTORY

Zakázané xxxx xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx modulátory:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-oxo);

exemestan;

formestan;

letrozol;

testolacton,

ale xx x omezením xxxxx xx ně.

2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx.

3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:

Xxxxxxxxxx; xxxxxxxxxxx x klomifen, ale xx s xxxxxxxx xxxxx xx xx.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, xxx ne

s xxxxxxxx xxxxx xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. AICAR; x Xxxxxxxx Receptoru xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (PPARδ), např. XX 1516;

5.2 Xxxxxxxx x mimetika insulinů;

5.3 Xxxxxxxxx;

5.4 Xxxxxxxxxxxx.

X5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx xxxxxxxxx a maskovací xxxxx xxxx xxxxxxxx, xxxxxx xxxx xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, hydroxyethylškrobu x xxxxxxxxx), xxxxxxxxxx, xxx xx x omezením xxxxx na xx.

• Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, chlorothiazid), xxxxxxxxxx x xxxxxxx (xxxx. xxxxxxxxx), xxx xx s omezením xxxxx na xx.

X xxxxxxxx:

• xxxxxxxxxxxx, xxxxxxxxx x xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (např. dorzolamidu x xxxxxxxxxxxx)

• Xxxxxxxxx xxxxxx xxxxxxxxxxxx pro xxxxx xxxxxxxxx

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx stanoveným xxxxxxxx limitem (xx. xxxxxxxxxx, salbutamol, katin, xxxxxxx, metylefedrin a xxxxxxxxxxxxx) xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo

případně Xxx Xxxxxxx ve xxxxxxx s xxxxxxxxxx xxxx xxxxx maskovací xxxxxx, xxxx xxxxxxxxxx xx Xxxxxxxxx laboratorní xxxxx, xxxxx Sportovec xxxx schválenou Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx látku xxxxx x xx, která xxx xxxx udělena xx xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX S XXXX X KREVNÍMI XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx xxxx znovuzavedení xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx krvinek a xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx systému.

2. Xxxxx xxxxxxxxx xxxxxxxx, přenosu xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx produkty (xxxx. xxxxxx xxxxxxxx založené xx hemoglobinu x xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), perfluorochemikálie x xxxxxxxxxxx (XXX13), xxx xx x xxxxxxxx pouze xx xx. Xxxxxxxxx suplementace xxxxxxxx zakázána xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx s xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, xx účelem xxxxxxx xxxxxxxxx x xxxxxxxx Vzorků odebraných xxx Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx záměnu x/xxxx xxxxxx (xxxx. xxxxxxxxxx) moči, ale xx x omezením xxxxx xx ně.

2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx nemocničních xxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx normálních xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX X METODY XXXXXXXX XXX SOUTĚŽI

Kromě xxxxxxxxx X0 xx X5 a X1 xx X3 xxxxxxxxx xxxx

xxxx Xxx Xxxxxxx xxxxxxxx i xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx xxxxxx případných xxxxxxxxx xxxxxxx, xxxx. x- x X-, xxxx xxxxxxxx.

Xxxxxxxxxxx zahrnují:

(a) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/,

xxxxxxxxxx,

xxxxxxxxxxx,

xxxxxx,

xxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxx (x-),

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxxxx, 

x-xxxxxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx odstavci, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (xxx ne x xxxxxxxx pouze xx ně):

Adrenalin (xxxxxxxxx)****,

xxxxxxxxxxx,

xxxxxxxxxxxxxxxxx,

xxxxxxx***,

xxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx x xxxx xxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxx,

xxxxx**,

xxxxxxx x xxxx xxxxxxx (xxxx. xxxxxxxx, xxxxxxxxx x xxxx-xxxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxxxxx,

xxxxxxxxxxxx,

xxxxxxxxxxxx***,

xxxxxxxxxxxxxxxxxxxxxxxx,

xxxxxxxxxxxx,

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx),

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxx (xxxxxxxxxxxxx),

xxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxxxx,

xxxxxxxxxxxxx*****,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxx (metylendioxyamfetamin),

tuaminoheptan

a xxxxx látky s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx.

X výjimkou:

• klonidinu

• derivátů xxxxxxxxx x případě xxxxxx xxxxxxxx/xxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2017*.

* Bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: Xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2017 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx: xx xxxxxxxx xxxxx xxx koncentraci xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.

*** Xxxxxxx x methylefedrin: xxxx xxxxxxxx xxx koncentraci xxxxx xxx 10 xxxxxxxxxx x 1 xx moči.

**** Xxxxxxxxx (xxxxxxxxx): není xxxxxxx xxx xxxxxxxx podání, xxxx. nosní, oční xxxxxxxx xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx anestetiky.

***** Pseudoefedrin: xx zakázán, xxxxx xxxx xxxxxxxxxxx x xxxx je xxxxx xxx 150 mikrogramů xx xxxxxxxx.

X7. NARKOTIKA

Zakázané xx následující:

Buprenorfin,

dextromoramid,

diamorfin(heroin),

fentanyl x xxxx xxxxxxxx,

xxxxxxxxxxx,

xxxxxxx,

xxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxx.

X8. KANABINOIDY

Zakázané xx xxxxxxxxxxx:

• Xxxxxxxx (xxxx. xxxxx, xxxxxx x xxxxxxxxx) nebo xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX).

• Xxxxxxxxxxxxxx, xxxx. "Xxxxx", JWH018, XXX073 x HU-210.

S9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, nitrožilní xxxx xxxxxxxxxxxxx aplikací xxxx xxxxxxxx.

XXXXX ZAKÁZANÉ X&xxxx;XXXXXXXX XXXXXXXX

X1. XXXXXXX

Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx sportech. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Prahová xxxxxxx xxx porušení xxxxxxxxxxx xxxxxxxx je xxxxxxxxxxxx koncentraci alkoholu x xxxx 0,10 x/x.

• Xxxxxxxxxxxx sport (FIA)

• Lukostřelba (XX)

• Xxxxxxx sporty a xxxxxxxxxxxx (FAI)

• Vodní motorismus (XXX)

X2. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx xxxx xxxxxxxx pouze x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx, x kde xx xx xxxxxxxx x Xxxx xxxxxx.

• Xxxxxxxxxxxx xxxxx (FIA)

• Billiard (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (XXX) - xxxxx na lyžích x akrobatické lyžování-skoky x X-xxxxx, a xxxxxxxxx X-xxxxx x "xxx air"

• Podvodní sporty (xxxxxxxxx xxxxxxxx) (CMAS) x xxxxxxxxxxxx konstantní xxxx x xxxxxxxxx xxxx bez xxxxxxx, xxxxxxxxx xxxxx x xxxxxxxxx xxxx xxx xxxxxxx, xxxx xxxxxxxxx, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx apnoe, střelba xxxxxxxx na xxxx x xxxxxxxxxx váha.

• Střelba (XXXX, IPC)*

• Šipky (XXX)

* Xxxxxxxx také Mimo xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:

Xxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxx,

xxxxxxxxxx,

xxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxx,

xxxxxxxxxx, 

xxxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxxxx,

xxxxxxx,

xxxxxxx,

xxx ne s xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 80/2017 Xx. x. x. xxxxx xxxxxxxxx xxxx 4.1.2018.

Xxxxxx předpis x. 80/2017 Sb. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 36/2019 Sb. m. s. x účinností xx 26.7.2019.

Xxxxx jednotlivých xxxxxxxx xxxxx jiných xxxxxxxx předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx jich xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx, xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx, xxxx xxxxxxxxx v anglickém xxxxx x x xxxxxxxxx do xxxxxxx xxxxxx xxx č. 58/2007 Sb. m. s.

Xxxx xxxxx překladu Úmluvy xx xxxxxxx jazyka xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.